Large-scale epidemiological studies firmly established the association between low plasma
levels of high-density lipoprotein-cholesterol (HDL-C) and elevated risk of cardiovascular …

Reduced levels of high-density lipoprotein cholesterol (HDL) are associated with a
substantially increased risk of coronary disease and cardiovascular events. Furthermore …

Lessons from recent end point trials of lipid-lowering drugs indicate that patients at very high
risk for coronary artery disease (CAD) benefit from treatment that lowers low-density …

Classical epidemiology has established the incremental contribution of the high-density
lipoprotein (HDL) cholesterol measure in the assessment of atherosclerotic cardiovascular …

The plasma level of high-density lipoprotein (HDL)-cholesterol is inversely correlated with
coronary artery disease, the leading cause of death worldwide. HDL particles are thought to …

Our understanding of the relationship between the atheroprotective activities of HDL and
heterogeneity of HDL particles has advanced greatly. HDL particles are highly …

vascular Events (PROactive) trial, a prospective, randomized, double-blind, placebo-
controlled trial of treatment with pioglitazone for 3 years in type 2 diabetics with a history of …

In the past decade, high-density lipoproteins (HDL) have emerged as a new potential
therapeutic target for the treatment of cardiovascular disease. The key role of HDL as a …

The beneficial effect of lowering low-density lipoprotein cholesterol (LDL-C) in clinical trials
(1) has transformed our ability to reduce cardiovascular risk. However, increasing …

Population studies have consistently shown that high-density lipoprotein (HDL) cholesterol
levels are a strong, independent inverse predictor of cardiovascular disease. Every 1 mg/dl …